ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 01. Juni Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

SUN JEONGHOON [VerfasserIn]
HO WEI-HSIEN [VerfasserIn]
ALHAWAGRI MUHAMMAD A [VerfasserIn]
KONG PHILIP LING [VerfasserIn]
RHINN HERVE [VerfasserIn]
LONG HUA [VerfasserIn]
SRINIVASAN KARPAGAM [VerfasserIn]
MITRA ANANYA [VerfasserIn]
BERMINGHAM DANIEL P [VerfasserIn]
HEGER KLAUS-DIETER [VerfasserIn]
SALAZAR SANTIAGO VIVEROS [VerfasserIn]
CIGNARELLA FRANCESCA [VerfasserIn]
TASSI ILARIA [VerfasserIn]
SCHWABE TINA [VerfasserIn]
YEE ANGIE GRACE [VerfasserIn]
ROSENTHAL ARNON [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61P: Specific therapeutic activity of chemical compounds (...)
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-06-01, Last update posted on www.tib.eu: 2023-07-01, Last updated: 2023-07-08

Patentnummer:

EP4003519

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA01550655X